User profiles for D P Brooks
 | David P BrooksDirector, Business Development Verified email at its.jnj.com Cited by 7199 |
Antioxidant activity of carvedilol in cardiovascular disease
Oxidative and inflammatory stresses are cardinal in the pathogenesis of hypertension and
atherosclerosis. Oxidative stress also leads to the induction of inflammation through the …
atherosclerosis. Oxidative stress also leads to the induction of inflammation through the …
Pharmacology of synthetic organic selenium compounds
…, S Sinha, RR Ruffolo, JP Hieble, DP Brooks… - Progress in Drug …, 1991 - Springer
The similarity in the chemical properties of sulfur and selenium has tempted medical
chemists for many years to prepare, for comparative purposes, a wide variety of selenium …
chemists for many years to prepare, for comparative purposes, a wide variety of selenium …
N-((1S)-1-{[4-((2S)-2-{[(2, 4-dichlorophenyl) sulfonyl] amino}-3-hydroxypropanoyl)-1-piperazinyl] carbonyl}-3-methylbutyl)-1-benzothiophene-2-carboxamide …
…, BJ Votta, SA Sheardown, X Xu, DP Brooks… - … of Pharmacology and …, 2008 - ASPET
The transient receptor potential (TRP) vanilloid 4 (TRPV4) member of the TRP superfamily
has recently been implicated in numerous physiological processes. In this study, we describe …
has recently been implicated in numerous physiological processes. In this study, we describe …
Cloning and functional characterization of a sodium-dependent phosphate transporter expressed in human lung and small intestine
JA Feild, L Zhang, KA Brun, DP Brooks… - … and biophysical research …, 1999 - Elsevier
A cDNA clone with 53% amino acid identity to the human type II sodium-dependent
phosphate transporter (NaPi-3) was isolated from human small intestine and lung. Functional …
phosphate transporter (NaPi-3) was isolated from human small intestine and lung. Functional …
Inhibition of gene markers of fibrosis with a novel inhibitor of transforming growth factor-β type I receptor kinase in puromycin-induced nephritis
…, C Tweed, P Thornton, J Harling, DP Brooks… - … of Pharmacology and …, 2005 - ASPET
SB-525334 (6-[2-tert-butyl-5-(6-methyl-pyridin-2-yl)-1H-imidazol-4-yl]-quinoxaline) has
been characterized as a potent and selective inhibitor of the transforming growth factor-β1 (TGF-…
been characterized as a potent and selective inhibitor of the transforming growth factor-β1 (TGF-…
Sex difference in the development of deoxycorticosterone-salt hypertension in the rat.
Y Ouchi, L Share, JT Crofton, K Iitake, DP Brooks - Hypertension, 1987 - Am Heart Assoc
… Crofton JT, Dustan HP, Share L, Brooks DP. Vasopressin secretion in normotensive
black and white men and women on normal and low sodium diets. J Endocrinol 1986;108:191—199 …
black and white men and women on normal and low sodium diets. J Endocrinol 1986;108:191—199 …
Molecular mechanisms of antidiuretic effect of oxytocin
…, SN Summer, TD Westfall, DP Brooks… - Journal of the …, 2008 - journals.lww.com
Oxytocin is known to have an antidiuretic effect, but the mechanisms underlying this effect
are not completely understood. We infused oxytocin by osmotic minipump into vasopressin-…
are not completely understood. We infused oxytocin by osmotic minipump into vasopressin-…
The pharmacology of fenoldopam
…, RR Ruffolo Jr, DP Brooks - American Journal of …, 1990 - academic.oup.com
… markedly in creasing glomerular filtration rate (DP Brooks, unpub lished observations). …
amphotericin Btreated dogs (AJ Nichols and DP Brooks, unpub lished observations). Moreover, …
amphotericin Btreated dogs (AJ Nichols and DP Brooks, unpub lished observations). Moreover, …
Hypertensive end-organ damage and premature mortality are p38 mitogen-activated protein kinase–dependent in a rat model of cardiac hypertrophy and dysfunction
Background Numerous pathological mediators of cardiac hypertrophy (eg, neurohormones,
cytokines, and stretch) have been shown to activate p38 MAPK. The purpose of the present …
cytokines, and stretch) have been shown to activate p38 MAPK. The purpose of the present …
The discovery of GSK221149A: a potent and selective oxytocin antagonist
Optimisation of a series of oxazole diketopiperazines has led to the discovery of a very
potent and selective oxytocin antagonist GSK221149A. GSK221149A has been shown to …
potent and selective oxytocin antagonist GSK221149A. GSK221149A has been shown to …